Fairvalue-Calculator Fairvalue-Calculator
EN DE

Allarity Therapeutics, Inc (ALLR) Fair Value & Analysis

Healthcare · US · Market cap $22.8M

Price$1.30
Fair Value$0.6000
Upside-53.8%
Quality95/100
Evidence: Low Range $0.3900 – $0.7500

Fair value as of: Jun 25, 2026

Analysis

Allarity Therapeutics, Inc (ALLR) currently trades at $1.30, while our model-based Fair Value estimate is $0.6000 — implying the stock looks roughly 53.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Allarity Therapeutics, Inc (ALLR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.6000 versus a price of $1.30 — about −54% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALLR?
Our 21-model fair value for Allarity Therapeutics, Inc is $0.6000 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.30.
What is the quality score of ALLR?
Allarity Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.